Spravato vs Ketamine Infusions: Practical Differences

Patients comparing Spravato with ketamine infusions are usually not choosing between two rival drugs. They are choosing between two regulatory worlds that happen to share a molecule family. One is an approved medicine with defined indications, a controlled-access and supervised-administration framework and, in several European health systems, a public funding route. The other is an older generic anaesthetic used off-label, mostly in private clinics, on the strength of an academic evidence base. This page sets the two side by side on the practical points; the clinical detail lives in our full esketamine evidence review and ketamine evidence review, and every clinical fact here is drawn from those two pages.

One molecule family, two products

Racemic ketamine is a 50:50 mix of two mirror-image molecules. Esketamine is one of them, isolated and developed into a distinct nasal-spray medicine that went through the full regulatory trial programme and received an EU-wide marketing authorisation on 18 December 2019. Racemic ketamine has never been through regulatory approval as an antidepressant; it remains a licensed anaesthetic, so depression treatment with it is off-label. Legal, but outside the licence.

Related is not interchangeable. Both are NMDA-receptor antagonists with overlapping glutamatergic effects: the reason both are dissociatives rather than classic psychedelics, a distinction we unpack in is ketamine a psychedelic?. Their rapid antidepressant action is thought to involve downstream changes in AMPA signalling, neurotrophic signalling and synaptic function, although the full mechanism remains incompletely understood. But they carry different evidence bases, different supervision rules and different price tags, and a clinic offering one is not offering the other.

Side by side

	Spravato (esketamine)	Ketamine infusions (racemic)
Approval	EU marketing authorisation since December 2019	Licensed as an anaesthetic only; off-label for depression across Europe
Licensed indications	Two EU-authorised indications: (1) treatment-resistant depression in adults, added to an SSRI or SNRI, after at least two failed antidepressants in the current episode; (2) with an oral antidepressant, acute short-term treatment for rapid reduction of depressive symptoms in a moderate-to-severe episode that, in clinical judgement, constitutes a psychiatric emergency. It has not been demonstrated to prevent suicide or reduce suicidal ideation or behaviour	None for depression; protocols are clinic-defined
Route	Nasal spray (28–84 mg), self-administered under direct staff supervision, never dispensed for home use	Intravenous infusion administered by clinic staff
Setting	Clinic session with post-dose observation; patients must not drive, operate machinery or undertake hazardous activities until the next day following a restful sleep	Clinic session with monitoring and a recovery period; follow the clinic's discharge instructions, including not driving yourself home
Core evidence	Regulatory programme of roughly 1,800 patients with mixed results inside it: TRANSFORM-2 met its primary endpoint, while TRANSFORM-1 and the older-adult TRANSFORM-3 did not reach statistical significance; SUSTAIN-1 showed relapse prevention in a randomised-withdrawal design among patients who had already achieved stable response or remission; the later active-comparator trial ESCAPE-TRD beat quetiapine on remission	Replicated rapid effect since Zarate 2006, confirmed by Cochrane and later meta-analyses; benefit of a single infusion usually fades within one to two weeks
Insurance	Reimbursed under defined eligibility criteria in several European health systems	Public funding for IV ketamine in depression remains uncommon and varies by country and specialist pathway; Norway funds it publicly since August 2025, and France opened a narrow compassionate framework in March 2026
Typical cost to patient	Standard co-payments where reimbursed; expensive self-pay otherwise	Private per-infusion or per-programme fees; see our cost guide
Monitoring and risk framework	Blood pressure measured before and after each session; dissociation is common but not universal (27% in the EU product information), alongside dizziness, nausea, headache, somnolence, altered taste, vertigo, vomiting and transient blood-pressure elevation; rare post-marketing respiratory depression has occurred; misuse controls built into the licence; contraindicated in aneurysmal vascular disease, after intracerebral haemorrhage, and after any cardiovascular event (including myocardial infarction) within the previous six weeks	Blood pressure and heart rate rise during infusion; dissociation expected; repeated use calls for monitoring of urinary symptoms (ketamine uropathy) and dependence risk
In our directory	200+ Spravato centres, concentrated in designated-centre countries (as listed on 28 July 2026)	~40 ketamine clinics spread across many countries (as listed on 28 July 2026)

The geography deserves a second look. Most Spravato centres sit in a handful of countries (Poland, Switzerland, the Netherlands, Germany and Italy) because national reimbursement programmes concentrate treatment in designated sites, within the medicine's controlled-access and supervised-administration framework and subject to national rules. The ketamine clinics are spread across many more countries because off-label practice follows the private market instead: it appears wherever licensed doctors set up, including England, where the public system reimburses neither. One caveat on the numbers: directory counts date from 28 July 2026 and measure verified listings, not treatment capacity, waiting times or affordability.

When each route usually comes up

What follows describes practice as our country and evidence pages record it, not a recommendation of either treatment.

The Spravato route is the one European public systems have built a door for. Where a patient matches the reimbursed indication, at least two failed antidepressants in the current episode, with treatment added to an ongoing SSRI or SNRI, the national reimbursement machinery can engage: prescription by a psychiatrist, treatment in an appropriate clinical setting under direct healthcare-professional supervision, subject to national rules, with observation time after each session. Germany's G-BA, which initially rated the added benefit "not proven" in 2021, upgraded it to "considerable added benefit" in 2023 after the ESCAPE-TRD data, and several payers moved on the strength of that head-to-head result. Czechia added reimbursement in 2025.

Ketamine infusions come up in different circumstances. In England and Wales there is no publicly funded esketamine, so the private ketamine market is the main route that exists at all. Elsewhere, private clinics apply their own criteria after their own screening, which can matter for people who fall outside a national programme's limits. Some clinics pair infusions with structured psychotherapy as ketamine-assisted psychotherapy; our evidence review rates that pairing promising but under-evidenced, since no large trial cleanly separates the drug effect from the psychotherapy. And Norway is a notable exception among the countries reviewed: the national system rejected Spravato, then decided in August 2025 that its specialist health service may use off-label IV ketamine for treatment-resistant depression, delivered in hospital or district psychiatric centres with registry or clinical-study follow-up while long-term evidence develops. Narrower national exceptions also exist and evolve: France introduced a compassionate prescribing framework in March 2026 for injectable ketamine in adults with severe suicidal ideation.

One caution applies to both routes equally. A responsible provider screens cardiovascular health, current medicines and psychiatric history before any first dose, and for repeated ketamine programmes should track urinary symptoms over time. A provider that skips screening is a warning sign, whichever product is on offer.

Frequently asked questions

Is Spravato just patented ketamine?

No. Esketamine is one of the two molecules that make up racemic ketamine, isolated and taken through its own full trial programme to become an approved nasal-spray medicine. Racemic ketamine is the older generic anaesthetic, used off-label for depression by infusion. They share a mechanism; they do not share an evidence base or a regulatory status.

Which has the stronger evidence?

They are strong in different ways. Esketamine's programme is what regulators require, with mixed results inside it: TRANSFORM-2 met its primary endpoint, while TRANSFORM-1 and the older-adult TRANSFORM-3 did not reach statistical significance; SUSTAIN-1 showed relapse prevention in a randomised-withdrawal design among patients who had already achieved stable response or remission; and the later active-comparator trial ESCAPE-TRD beat quetiapine on remission, with moderate rather than dramatic effect sizes. Ketamine's rapid antidepressant effect is the best-established fact in the field, shown since Zarate 2006 and confirmed by the Cochrane review, but the trials are smaller, the benefit of a single infusion usually fades within one to two weeks, and maintenance strategy remains unsettled.

Direct comparative evidence remains limited and is mostly observational. A 2025 systematic review found broadly comparable acute response and remission rates, with a possible faster onset for IV ketamine but no clear overall superiority, and a small 2026 retrospective cohort likewise found improvement with both treatments and no statistically significant between-group difference. Large randomised head-to-head trials are still needed.

Why is Spravato easier to get covered?

Because reimbursement systems pay for licensed medicines against their approved indications. Esketamine has them; ketamine has none for depression, so its use is off-label and public funding for it remains uncommon, varying by country and specialist pathway. The clearest exception is Norway's August 2025 decision to allow off-label IV ketamine in its specialist service; France's March 2026 compassionate framework for injectable ketamine is a narrower one.

Can I take either at home?

No. Spravato is self-administered under direct supervision and never dispensed for home use, with blood-pressure checks and an observation period built into the licence, partly because of misuse risk. An intravenous ketamine infusion likewise belongs in a monitored clinical setting; repeated dosing carries dependence and bladder-damage risks that need clinical oversight. This comparison does not cover compounded oral, sublingual or intranasal ketamine products that may be supplied for home use in some jurisdictions.

How do I find out which route is open where I live?

Coverage is national, so start with your country. Our eligibility check walks through the questions that decide it, the Spravato centre listings and ketamine clinic listings show what operates near you, and the two evidence reviews linked above cover what each treatment can and cannot claim.

Sources

This comparison is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Approved indications, reimbursement rules and clinical evidence change; always verify current information with your national regulator or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

Reviewer's note. This is a clear and practical comparison of two treatments that are often confused. Its side-by-side format helps readers understand how esketamine and racemic ketamine differ in formulation, evidence, regulation, monitoring and access, while reinforcing that they are not interchangeable and that either treatment requires careful specialist assessment.

— Dr. Christopher Gauci, MD MRCS(Ed) EDAIC, anaesthetist and intensive care specialist, PsyAccess medical reviewers

Medically reviewed by Dr. Christopher Gauci, MD MRCS(Ed) EDAIC, on 16 August 2026.

Spravato (Esketamine) vs Ketamine Infusions: The Practical Differences

On this page